Loading…
Back To Schedule
Wednesday, June 30 • 10:00am - 11:00am
#310 SL: Patient-Focused Benefit-Risk Assessment and Risk Management: Methodology for Engaging with Patients: What has been Learned?

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Component Type: Session
Level: Intermediate
CE: ACPE 1.00 Knowledge UAN: 0286-0000-21-600-L04-P; CME 1.00; IACET 1.00; RN 1.00

Benefit-risk evaluation of medicines should incorporate patients input, values, and preferences. This session will discuss experience and methods used so far and will describe priorities to further enhance implementation pre- and post- authorization. Join the DIA Patient Engagement Community for a follow up round table discussion (session #346 RT L) on Wednesday, June 30, 3:00PM - 4:00PM EDT.

Learning Objectives

Recognize the importance and added value of incorporating patients views in benefit-risk throughout the lifecycle of a medicine; Discuss current experience and learnings from incorporating patient input in benefit risk; Discuss existing methodology; Identify implementation challenges, gaps and needs; Discuss the way forward, with focus on pharmacovigilance and risk minimization activities.

Chair

Juan Garcia-Burgos, MD, PhD

Speaker

Update from CIOMS
Lembit Rago, DrMed, MD, PhD

Update from FDA
Theresa Mullin, PhD

Update from Health Canada
Talia Lacroix, MPA

Update from Eurodis
François Houyez



Speakers
avatar for Juan Garcia-Burgos

Juan Garcia-Burgos

Head of Public and Stakeholders Engagement, European Medicines Agency, Netherlands
Juan Garcia Burgos is a Qualified Medical Doctor from Autonoma University in Madrid, specialised in urology. Juan worked as a urologist surgeon at the Maranon hospital in Madrid. He joined the European Medicines Agency in 2002 and was responsible for coordinating the preparation of... Read More →
avatar for François Houyez

François Houyez

Information and Access Director, Health Policy Advisor, European Organisation for Rare Diseases (EURODIS), France
François Houÿez is working at the European Organisation for Rare Diseases EURORDIS where he is Director of Treatment Information and Access, Policy Advisor. He has always been working as a patient advocate since the early 90s, first in the HIV/AIDS advocacy, and in rare diseases... Read More →
avatar for Talia Lacroix

Talia Lacroix

Senior Policy Analyst, Health Product and Food Branch, Health Canada, Canada
Talia Lacroix is a Senior Policy Analyst in Health Canada’s Health Products and Food Branch, the area that regulates the safety, quality, and efficacy of drugs and devices in Canada. Talia has spent the last 15 years contributing to regulatory frameworks, guidance, and policy; including... Read More →
avatar for Theresa Mullin

Theresa Mullin

Associate Director for Strategic Initiatives, CDER, FDA, United States
Dr. Mullin is Associate Center Director for Strategic Initiatives. She leads efforts including Patient-Focused Drug Development, Rare Disease Cures Accelerator, and CDER’s International Program. She leads the FDA delegation to ICH and currently chairs the ICH Management Committee... Read More →
avatar for Lembit Rago

Lembit Rago

Secretary General, Council for International Organizations of Medical Sciences (CIOMS), Switzerland
Dr Lembit Rägo was a Professor of Clinical Pharmacology and Director General of the Estonian State Agency of Medicines until joining WHO Geneva in 1999. When retiring WHO in 2016 Dr Rägo served as the Head of the WHO’s Unit, Regulation of Medicines and Other Health Technologies... Read More →


Wednesday June 30, 2021 10:00am - 11:00am EDT
TBD Virtual Event Horsham, PA 19044
  01: ClinSafety-PV, Session |   05: Patient Engagement, Session